Next Article in Journal
Role of CA 19.9 in the Management of Resectable Pancreatic Cancer: State of the Art and Future Perspectives
Next Article in Special Issue
Fecal Bacterial Community and Metagenome Function in Asians with Type 2 Diabetes, According to Enterotypes
Previous Article in Journal
Association between Vitamin C Deficiency and Mortality in Patients with Septic Shock
Previous Article in Special Issue
Diabetes: A Multifaceted Disorder
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 10
Issue 9
10.3390/biomedicines10092089
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Type 2 Diabetes Mellitus and COVID-19: A Narrative Review

by
Cristina Rey-Reñones
1,2,3,
Sara Martinez-Torres
2,
Francisco M. Martín-Luján
1,2,3,
Carles Pericas
4,
Ana Redondo
5,
Carles Vilaplana-Carnerero
4,6,
Angela Dominguez
4,7 and
María Grau
7,8,9,*
1
Research Support Unit-Camp de Tarragona, Catalan Institute of Health (ICS), 43005 Tarragona, Spain
2
IDIAP Jordi Gol, Catalan Institute of Health (ICS), USR Camp de Tarragona, 43202 Reus, Spain
3
School of Medicine and Health Sciences, Universitat Rovira i Virgili, 43201 Reus, Spain
4
Department of Medicine, University of Barcelona, 08036 Barcelona, Spain
5
Hospital Universitario Bellvitge, Catalan Institute of Health (ICS), 08907 Barcelona, Spain
6
IDIAP Jordi Gol, Catalan Institute of Health (ICS), 08007 Barcelona, Spain
7
Biomedical Research Consortium in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain
8
Serra Húnter Fellow, Department of Medicine, University of Barcelona, 08036 Barcelona, Spain
9
August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain
*
Author to whom correspondence should be addressed.
Biomedicines 2022, 10(9), 2089; https://doi.org/10.3390/biomedicines10092089
Submission received: 5 July 2022 / Revised: 19 August 2022 / Accepted: 20 August 2022 / Published: 26 August 2022
(This article belongs to the Special Issue Pathological Mechanisms in Diabetes)
Browse Figures
Review Reports Versions Notes

Abstract

:
Type-2 diabetes mellitus (T2DM) is a chronic metabolic disorder. The incidence and prevalence of patients with T2DM are increasing worldwide, even reaching epidemic values in most high- and middle-income countries. T2DM could be a risk factor of developing complications in other diseases. Indeed, some studies suggest a bidirectional interaction between T2DM and COVID-19. A growing body of evidence shows that COVID-19 prognosis in individuals with T2DM is worse compared with those without. Moreover, various studies have reported the emergence of newly diagnosed patients with T2DM after SARS-CoV-2 infection. The most common treatments for T2DM may influence SARS-CoV-2 and their implication in infection is briefly discussed in this review. A better understanding of the link between TD2M and COVID-19 could proactively identify risk factors and, as a result, develop strategies to improve the prognosis for these patients.

1. Introduction

In the last decades, type-2 diabetes mellitus (T2DM) has become a chronic metabolic disorder caused by the interaction of different genetic and environmental factors. The incidence and prevalence of patients with T2DM are increasing worldwide, even reaching epidemic values in most high- and middle-income countries [1]. The World Health Organization (WHO) estimates that T2DM will be the seventh leading cause of death by 2030 worldwide (Figure 1) [2]. The main reasons for this increase seem the high prevalence of obesity and the unhealthy lifestyles. Uncontrolled and prolonged T2DM can lead to serious complications, some of them being life-threatening [3]. As a result, the healthcare cost of T2DM and the related diseases is growing every year [4]. Strategies to control T2DM include appropriate life-style changes as well as medication intake when necessary [5].
T2DM could be a risk factor for developing complications in other diseases. At the onset of the pandemics, the USA Centers for Disease Control and Prevention (CDC) described that one third of patients infected with COVID-19 had comorbidities. Thus, people with at least one underlying condition account for 78% of admissions to the intensive care unit (ICU) and 94% of deaths. T2DM was the most frequently reported, being the 10.9% of the cases [6]. In addition, a fast-growing evidence reports a bidirectional interplay between T2DM and COVID-19. Clinical data so far suggest that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may result in metabolic dysregulation and in impaired glucose homeostasis [7].
The objective of this review is to provide an overview of the most recent studies that point to T2DM as a risk factor and poor prognosis of COVID-19, as well as, to summarize the potential mechanisms involved in this relationship.

2. T2DM as a Risk Factor for the Development and Prognosis of COVID-19

Several risk factors have been associated with an increased risk of SARS-CoV-2 infection and complication. For instance, male sex, older age, deprivation and comorbidities such as cardiopathy, hypertension, chronic obstructive pulmonary disease, immunosuppression or T2DM [8,9]. Thus, 33.8% of 5700 of patients with COVID-19 admitted to 12 hospitals within the Northwell Health system in New York had T2DM [10]. In addition, a random meta-analysis of 18 different studies determined that the risk of severe disease was 2.4-fold higher in patients with T2DM compared with those without [11], whereas another one showed a 2.6-fold higher severity risk by increased fasting blood glucose at admission [12].

2.1. Risk of Death and Complications in T2DM Patients with COVID-19

So far, different studies have shown that people with T2DM have higher risk of COVID-19 mortality compared with non-diabetic individuals [11,12,13,14,15,16,17,18,19]. Nevertheless, Al-Salameh et al., reported that COVID-19-related death in patients with T2DM was lower than in general population, but the rate of intensive care unit (ICU) admission was increased [20]. As highlighted by Diedisheim et al., the age may play a key role because after age 50 years, diabetes-related risk might be weakened by all other comorbidities or conditions associated with aging [15] (Table 1).
In addition to the increased mortality associated with COVID-19, patients with T2DM also present with more complications from such infection, even requiring admission to the ICU or dying [10,20]. Moreover, uncontrolled hyperglycemia can also be a risk factor for an adverse COVID-19 prognosis. An observational study including more than 1000 patients hospitalized with COVID-19 in USA showed that 40% of patients had diabetes or uncontrolled hyperglycemia at admission, and hospital mortality was four times higher for DM patients. The same study showed that mortality was seven times higher for those without pre-existing T2DM who developed in-hospital hyperglycemia [14]. Similarly, a recent meta-analysis that included 14,502 patients confirmed these findings and showed a nonlinear relationship between fasting blood glucose at admission and severity: every mmol/L enhancement in glucose levels increased the risk of COVID-19 severity by 33% [12].

2.2. Potential Mechanisms Underlying Unfaborable Clinical Outcomes of COVID-19 in People with Diabetes

Epidemiological studies have determined the severity of COVID-19 due to a number of complications or comorbidities associated with T2DM. Co-occurrence of microvascular and macrovascular T2DM complications, including cardiovascular disease, renal failure, retinopathy and reduced renal function, could be responsible for the increased poor COVID-19 outcomes and mortality after infection [21,22,23].
T2DM, even in the stages of prediabetes, is characterized by a dysregulation of glucose homeostasis, chronic inflammatory and prothrombotic state accompanied with other affectations, such as metabolic, vascular, immune and hematological abnormalities, which could explain the negative response to infections [24]. Some of these alterations have been proposed to explain T2DM impact on COVID-19 prognosis, including glucotoxicity, endothelial damage, chronic inflammatory state, oxidative stress and abnormal cytokine production [25,26].
Hyperglycemia could directly exacerbate SARS-CoV-2 infection, promoting the expression and activation of, angiotensin-converting enzyme 2 (ACE2) cellular receptor, the main receptor of the SARS-CoV-2, and increasing the expression of the serine protease TMPRSS2, which mediates the cleavage of the viral spike protein [27]. Of note, high glucose levels increase the production of inflammatory cytokines and cellular mediators and pro-thrombotic processes, promoting the development of acute cardiovascular complications [28]. Moreover, chronic hyperglycemia could compromise the innate and humoral immune response inhibiting lymphocyte proliferation, reducing the activity of natural killer cells and affecting the function of monocyte/macrophage and neutrophils [24,29]. According to this, different reports demonstrated that elevated glucose levels in admission is an independent risk factor for critical progression and in-hospital mortality in COVID-19 patients [30,31,32,33]. Therefore, uncontrolled hyperglycemia takes part to other COVID-19 complications, such as atherosclerosis, diabetic nephropathy, peripheral arteriosclerosis, and diabetic ketoacidosis [30]. Thus, hyperglycemia management has been proposed to improve clinical COVID-19 outcomes.
Other evidences suggested that chronic endothelial dysfunction predisposes to severe COVID-19 disease. In this regard, hyperglycemia and insulin resistance leads to endothelial dysfunction and glycocalyx damage in patients with T2DM, leading to leucocyte adhesion and promoting procoagulant and antifibrinolytic state [34,35]. A recent study of in-hospital COVID-19 patients from China reported that the COVID-19 severity was correlated with increased blood levels of IL-6 and lactate dehydrogenase (LDH) [36]. Of note, patients with T2DM have a higher inflammatory response, mainly characterized by increased levels of interleukin-6 (IL-6), interleukin-2 (IL-2) and the tumor necrosis factor α (TNF-α) [37]. This fact could explain the rapid COVID-19 progression and severity in patients with T2DM.
Altogether, these alterations could explain why patients with T2DM have a worse prognosis of COVID-19 (Figure 2).

3. SARS-CoV-2 Infection as a Risk Factor of Morbidity and Mortality: Metabolic Deregulation and Homeostasis Alteration

Infection affects several pathophysiological pathways, during the course of the disease, which eventually leads to late complications. So far, clinical data suggest that SARS-CoV-2 may cause metabolic dysregulation and impairment of glucose homeostasis. A study suggests that infection may be a precipitating factor for acute hyperglycemia, worsening prognosis in poorly controlled T2DM patients [38]. Moreover, some studies focus on the role of glycemic control as a critical factor to reduce complications, severe outcomes and mortality during SARS-CoV-2 infection [39,40].
Other studies identified the endothelium, which expressed both the ACE2 receptor and the serine protease TMPRSS2, as a first key player on the homeostasis alteration. In healthy individuals, endothelium is considered to be major contributor to various physiological processes supporting homeostasis. Lambadiari et al. showed that SARS-CoV-2 can cause endothelial and vascular dysfunction, which was associated with impaired cardiac performance for four months after SARS-CoV-2 infection [41]. After infection, there is an increase of cytokine levels and immune cells, which could induce insulin resistance and hyperglycemia [42]. Similarly, studies about Severe Acute Respiratory Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS) point out how inflammatory cells may affect the liver, altering insulin-mediated glucose uptake, resulting in hyperinsulinemia and hyperglycemia [43].
Other studies suggest that there are possible underlying mechanisms that could explain the acute damage of pancreatic islets by SARS-CoV-2 and the consequent loss of insulin secretory capacity [40,44]. The exacerbated immune response through the virus-mediated release of chemokines and cytokines could also damage pancreatic cells and impair their ability to detect glucose and release insulin. Moreover, the immune response of the virus can further affect the ability of the liver and muscles to identify alterations [40,44]. Considering previous experience with inflammatory responses, COVID-19 inflammatory and viral immune responses can affect insulin sensitivity and deregulate glucose metabolism, leading to a vicious cycle of hyperglycemia and inflammatory response that destroys tissue integrity and physiological function during critical stages of infection. Thus, frequently used drugs in the treatment of COVID-19, such as corticosteroids or antiviral agents, can aggravate hyperglycemia and result in lipodystrophy and insulin resistance [45,46].
Regarding glucose homeostasis, severe SARS-CoV-2 infection contributes to insulin resistance and hyperglycemia by increased cytokines and unregulated compensatory hormonal response [21,47]. Moreover, glucotoxicity and the associated consequences, added to the increase of inflammatory cytokines by SARS-CoV-2 infection, oxidative stress, immune dysfunction and endothelial damage, predict an increase in metabolic complications, an increased risk of thromboembolism and multiorgan damage in individuals with T2DM [25,48].

4. Newly Emerging Patients with T2DM Infected with SARS-CoV-2

SARS-CoV-2 infection would have a direct effect of on glucose metabolism. A recent metanalysis have shown 492 cases of newly diagnosed diabetes from eight studies that included 3711 COVID-19 patients with a pooled proportion of 14.4% (95% confidence interval [5.9–25.8%]) [49]. Recent findings suggest a direct effect of SARS-CoV-2 on glucose metabolism resulting in new presentations of T2DM characterized by diabetic ketoacidosis, hyperosmolarity and unusually high insulin requirements to achieve glycemic control [49,50]. Although the evidence of a direct relationship between how SARS-CoV-2 is still sparse, Kazakou et al. described to possible links. First, the SARS-CoV-2 infection could damage B cells in the pancreas through the direct cytolytic effect of the virus. Second, the direct damage to the endocrine system during infection, which could contribute to the development of glucose and metabolic abnormalities in people previous infected (Figure 3) [42]. Understanding the effects of COVID-19 on glucose metabolism and homeostasis is essential to prevent and control complications associated with this infection and to help patients recovery [7].

5. How Antidiabetic Treatment Influences SARS-CoV-2 Infection

Blood glucose control may be crucial as a preventive measure for adverse outcomes related to COVID-19 [7]. Table 2 shows the influence of the most common treatments for T2DM on SARS-CoV-2 infection.

5.1. Metformin

As discussed above, inflammatory exacerbation due to increased cytokines levels has been recognized as one of the main keys to poor prognosis in COVID-19. The anti-inflammatory properties of metformin are already known, suggesting a beneficial effect for COVID-19 disease [52]. Despite this, immunomodulatory actions of metformin in the context of COVID-19 remain unclear. Some evidence point out the positive implications of metformin in COVID-19 as reduced insulin resistance and inhibition of virus entry through AMPK activation and phosphorylation of ACE2 [7]. Crouse et al., affirmed that although T2DM is a factor risk for COVID-19-related mortality, the risk is drastically reduced in subjects treated with metformin before the diagnosis of COVID-19, considering that metformin can provide a protective effect in this high-risk population [53]. In addition, a meta-analysis estimated a risk reduction associated with this treatment in individuals with T2DM and SARS-CoV-2 infection (Odds ratio (OR) = −0.37; 95% CI [−0.59; −0.16]) [54].
According to the practical recommendations for the management of T2DM in patients with COVID-19 a treatment cessation with metformin is recommended in dehydrated patients and follow the guidelines according to the infection, because lactic acidosis is likely to appear [55]. The same guide recommends careful surveillance of kidney function because of the high risk of chronic kidney disease or acute kidney damage [27].

5.2. Insulin

Insulin treatment is the first treatment option for controlling hyperglycemia in critical patients. Available evidence suggests that it is also the most appropriate hypoglycemic agent in hospitalized patients with severe T2DM and COVID-19 [56]. Recent studies have shown that severe cases of newly onset or pre-existing T2DM patients with COVID-19, high doses of intravenous insulin infusion are needed to control glycemic levels [42]. According to this, continuous glucose monitoring during hospitalization helps to ensure good control and minimize the risk of hypoglycemia in people on insulin therapy. Thus, insulin treatment results in an improvement in glycemic control in patients hospitalized in the ICU and offers the advantage of remote monitoring [57,58].
Some evidences indicate that patients with T2DM under insulin treatment for COVID-19 present worse clinical outcomes when compared with other antidiabetic drugs in early-stage of the disease. In fact, insulin treatment was associated with increased systemic inflammation and increased damage to vital organs, suggesting that insulin therapy for patients with COVID-19 and T2DM needs to be used with caution (27.2% versus 3.5%; adjusted Hazard Ratio = 5.38; 95% CI [2.75–10.54]) [59]. Thus, insulin treatment reflects a more advanced stage of the disease with associated co-morbidities, indicating the need of studies in this regard [60]. However, insulin remains the star treatment in serious hospitalized patients [27,48].

5.3. SGLT2 (Sodium-Glucose Cotransporter-2) Inhibitors

SGLT2 inhibitors are a type of oral medication indicated to reduce blood glucose in adults with T2DM. Patients treated with SGLT2 inhibitors have an increased risk of dehydration and euglycemic diabetic ketoacidosis in case of acute illness, especially if the disease accompanies anorexia and vomiting [61]. Some studies suggest that SGLT2 inhibitors may reduce viral load due to increased lactate concentrations and decreased intracellular pH. In addition to the already known anti-inflammatory properties, primarily on endothelial function, SGLT2 inhibitors therapy could play a protective role in COVID-19-related organ failure [25]. The meta-analysis performed by Nguyen et al. showed a significant mortality reduction in individuals with T2DM treated with SGLT2 inhibitors previous to hospital admission (OR = 0.60 [0.40–0.88]) [62]. Nevertheless, a double-blind, placebo-controlled clinical trial with dapagliflozin in COVID-19 hospitalized patients with one or more cardiometabolic risk factors did not show a significant reduction in organ dysfunction or death, or in clinical recovery [63]. The recommendations for the practice in the management of T2DM in patients with COVID-19 suggest the discontinuation of treatment with SGLT2 inhibitors in severely affected patients with COVID-19 and at risk of dehydration [27].

5.4. Sulfonylureas

Sulfonylureas are the oldest oral type of antidiabetic drugs. Sulfonylureas bind to the ATP-sensitive potassium channels on the pancreatic β-cells, resulting in membrane depolarization and, therefore, stimulating insulin secretion [64]. On the one side, a systematic review and meta-analysis highlight the potential for sulfonylurea treatment to reduce the risk of mortality in T2DM patients with COVID-19 (OR = 0.80; 95% CI [0.66; 0.96]) [54]. On the other side, as Drucker’s review points out, patients with T2DM and severe COVID-19 disease should avoid treatment with sulfonylureas and discontinue treatment in case of hospitalization due to the risk of hypoglycemia, especially in situations of low oral food intake or in combination with chloroquine or hydroxychloroquine treatments [48].

5.5. Thiazolidinediones

These drugs act as partial or selective agonists of the peroxisome activated by proliferator-γ (PPAR-γ) receptor, a nuclear receptor that regulates the transcription of several genes involved in glucose and lipid metabolism. Thiazolidinediones have shown to improve insulin resistance and have anti-inflammatory properties and anti-atherosclerotic effects, having the potential to mediate the protective effects of the cardiovascular system [25]. This treatment has been associated with weight gain and swelling, which has also led to an increase in heart failure. Therefore, its use is not recommended in patients with COVID-19, although the literature suggests that more clinical trials are needed to maximize the risk-benefit relationship of thiazolidinediones use in patients with COVID-19 [65].

5.6. Dipeptidyl Peptidase-4 (DPP4) Inhibitors

DPP4 is a transmembrane glycoprotein expressed in the spleen, lung, liver, kidneys, and immune cells or soluble circulating in the bloodstream. DPP4 has a crucial role in glucose homeostasis. DPP4 inhibitors in patients with DM2 have been used for a long time since 2006, with good tolerance and few adverse reactions reported [66]. The role of DPP-4 inhibition as an inflammation mitigator and potent antifibrotic agent is supported by several experimental studies [67].
Recent studies suggest that DPP4 inhibitors could benefit the treatment of mild or even severe cases of COVID-19. A metanalysis including 10 observational studies found that DDP-4 inhibitors reduce the risk for COVID-19-related mortality by 50% [67]. Other metanalysis also support the hypothesis that DDP-4 inhibitors could have a protective effect on COVID-19 (OR = 0.58; 95% CI [0.34–0.99]) [68]. Finally, the reduction in mortality was marginally significant in the metanalysis performed by Kan et al. (OR = 0.72; 95% CI [0.51–1.01]) [54]. Thus, further research is necessary to evaluate the role of DPP4 inhibitors in patients with T2DM and COVID-19 [69].

5.7. Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist

GLP-1 is an incretine hormone responsible of blood glucose reduction through its receptor that reduce blood. Beyond controlling glycemia, GLP-1 receptor agonist has great potential for treating hyperglycemia [70]. Indeed, a review concluded that GLP-1 receptor agonist was able to reduce blood glucose levels and in turn, the administration of insulin without increasing the incidence of hypoglycemia. A recent Bayesian Network Metanalysis GLP-1 receptor agonist treatment was liked to a decrease in COVID-19-related mortality in T2DM individuals compared to non-users (OR = 0.91; 95% CI [0.84; 0.98]) [71]. However, there is not sufficient evidence to recommend GLP-1 receptor agonist for critical patients with T2DM and COVID-19 [72]. Regarding the adverse effects, this treatment can trigger gastrointestinal side effects such as nausea and vomiting, and consequently, aspiration in this type of patients. For this reason, GLP-1 receptor agonists are not recommended for patients with mild or moderate COVID-19 [27]. Among the most outstanding findings about GLP-1 receptor agonists is the reduction of major cardiac events in patients with T2DM, and its anti-inflammatory action under conditions of low-grade inflammation such as atherosclerosis and non-alcoholic fatty liver disease [73,74].

6. Summary

This review provides the latest insights into the interaction between COVID-19 and T2DM, which is considered a major risk factor for COVID-19 disease. Furthermore, new data have identified hyperglycemia and insulin resistance in patients after SARS-CoV-2 infection, leading to an emerging form of T2DM. The pathophysiological effects of both diseases (e.g. inflammation, immune response, endothelial damage and glucotoxicity) have been proposed as the main potential mechanisms behind this bidirectional interplay. Moreover, research works have identified the interaction between several T2DM treatments and the prognosis of COVID-19, leading to more specific recommendations for the treatment of hyperglycemia during COVID-19. A better understanding of the link between TD2M and COVID-19 could proactively identify risk factors and, as a result, develop strategies to improve the prognosis for these patients.

Author Contributions

Conceptualization, M.G. and F.M.M.-L.; methodology, C.R.-R., S.M.-T. and M.G.; investigation, C.R.-R., S.M.-T. and M.G.; writing—original draft preparation, C.R.-R., S.M.-T., C.P., A.R. and M.G.; writing—review and editing, C.R.-R., S.M.-T., F.M.M.-L., A.R., C.P., C.V.-C., A.D. and M.G. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data sharing not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. International Diabetes Federation. IDF Diabetes Atlas, 10th ed.; International Diabetes Federation: Brussels, Belgium; Available online: https://www.diabetesatlas.org (accessed on 24 June 2022).
  2. Mathers, C.D.; Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006, 3, e442. [Google Scholar] [CrossRef] [PubMed]
  3. Baena-Díez, J.M.; Peñafiel, J.; Subirana, I.; Ramos, R.; Elosua, R.; Marín-Ibañez, A.; Guembe, M.J.; Rigo, F.; Tormo-Díaz, M.J.; Moreno-Iribas, C.; et al. Risk of cause-specific death in individuals with diabetes: A competing risks analysis. Diabetes Care 2016, 39, 1987–1995. [Google Scholar] [CrossRef] [PubMed]
  4. Bommer, C.; Sagalova, V.; Heesemann, E.; Manne-Goehler, J.; Atun, R.; Bärnighausen, T.; Davies, J.; Vollmer, S. Global economic burden of diabetes in adults: Projections from 2015 to 2030. Diabetes Care 2018, 41, 963–970. [Google Scholar] [CrossRef]
  5. Alam, S.; Hasan, K.; Neaz, S.; Hussain, N.; Hossain, F.; Rahman, T. Diabetes mellitus: Insights from epidemiology, biochemistry, risk factors, diagnosis, complications and comprehensive management. Diabetology 2021, 2, 36–50. [Google Scholar] [CrossRef]
  6. Chow, N.; Fleming-Dutra, K.; Gierke, R.; Hall, A.; Hughes, M.; Pilishvili, T.; Ritchey, M.; Roguski, K.; Skoff, T.; Ussery, E. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28, 2020. MMWR. Morb. Mortal. Wkly. Rep. 2020, 69, 382–386. [Google Scholar] [CrossRef]
  7. Kazakou, P.; Lambadiari, V.; Ikonomidis, I.; Kountouri, A.; Panagopoulos, G.; Athanasopoulos, S.; Korompoki, E.; Kalomenidis, I.; Dimopoulos, M.A.; Mitrakou, A. Diabetes and COVID-19; A bidirectional interplay. Front. Endocrinol. 2022, 13, 780663. [Google Scholar] [CrossRef] [PubMed]
  8. Baena-Díez, J.M.; Barroso, M.; Cordeiro-Coelho, S.I.; Díaz, J.L.; Grau, M. Impact of COVID-19 outbreak by income: Hitting hardest the most deprived. J. Public Health 2020, 42, 698–703. [Google Scholar] [CrossRef]
  9. Baena-Díez, J.M.; Gonzalez-Casafont, I.; Cordeiro-Coelho, S.; Fernández-González, S.; Rodríguez-Jorge, M.; Pérez-Torres, C.U.F.; Larrañaga-Cabrera, A.; García-Lareo, M.; de la Arada-Acebes, A.; Martín-Jiménez, E.; et al. Effectiveness of telephone monitoring in primary care to detect pneumonia and associated risk factors in patients with SARS-CoV-2. Healthcare 2021, 9, 1548. [Google Scholar] [CrossRef]
  10. Richardson, S.; Hirsch, J.S.; Narasimhan, M.; Crawford, J.M.; McGinn, T.; Davidson, K.W.; the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020, 323, 2052–2059. [Google Scholar] [CrossRef]
  11. de Almeida-Pititto, B.; Dualib, P.M.; Zajdenverg, L.; Dantas, J.R.; de Souza, F.D.; Rodacki, M.; Bertoluci, M.C.; Brazilian Diabetes Society Study Group (SBD). Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: A meta-analysis. Diabetol. Metab. Syndr. 2020, 12, 1–12. [Google Scholar] [CrossRef]
  12. Lazarus, G.; Audrey, J.; Wangsaputra, V.K.; Tamara, A.; Tahapary, D.L. High admission blood glucose independently predicts poor prognosis in COVID-19 patients: A systematic review and dose-response meta-analysis. Diabetes Res. Clin. Pract. 2020, 171, 108561. [Google Scholar] [CrossRef] [PubMed]
  13. Barron, E.; Bakhai, C.; Kar, P.; Weaver, A.; Bradley, D.; Ismail, H.; Knighton, P.; Holman, N.; Khunti, K.; Sattar, N.; et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: A whole-population study. Lancet Diabetes Endocrinol. 2020, 8, 813–822. [Google Scholar] [CrossRef]
  14. Bode, B.; Garrett, V.; Messler, J.; McFarland, R.; Crowe, J.; Booth, R.; Klonoff, D.C. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J. Diabetes Sci. Technol. 2020, 14, 813–821. [Google Scholar] [CrossRef] [PubMed]
  15. Diedisheim, M.; Dancoisne, E.; Gautier, J.-F.; Larger, E.; Cosson, E.; Fève, B.; Chanson, P.; Czernichow, S.; Tatulashvili, S.; Raffin-Sanson, M.-L.; et al. Diabetes increases severe COVID-19 outcomes primarily in younger adults. J. Clin. Endocrinol. Metab. 2021, 106, e3364–e3368. [Google Scholar] [CrossRef] [PubMed]
  16. Espiritu, A.I.; Chiu, H.H.C.; Sy, M.C.C.; Anlacan, V.M.M.; Macalintal, C.M.S.A.; Robles, J.B.; Cataniag, P.L.; Flores, M.K.C.; Tangcuangco-Trinidad, N.J.C.; Juangco, D.N.A.; et al. The outcomes of patients with diabetes mellitus in The Philippine CORONA Study. Sci. Rep. 2021, 11, 1–10. [Google Scholar] [CrossRef]
  17. Kim, T.S.; Roslin, M.; Wang, J.J.; Kane, J.; Hirsch, J.S.; Kim, E.J.; the Northwell Health COVID-19 Research Consortium. BMI as a Risk factor for clinical outcomes in patients hospitalized with COVID-19 in New York. Obesity 2020, 29, 279–284. [Google Scholar] [CrossRef]
  18. Williamson, E.J.; Walker, A.J.; Bhaskaran, K.; Bacon, S.; Bates, C.; Morton, C.E.; Curtis, H.J.; Mehrkar, A.; Evans, D.; Inglesby, P.; et al. Factors associated with COVID-19-related death using Open SAFELY. Nature 2020, 584, 430–436. [Google Scholar] [CrossRef]
  19. Wu, Z.; McGoogan, J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020, 323, 1239–1242. [Google Scholar] [CrossRef]
  20. Al-Salameh, A.; Lanoix, J.; Bennis, Y.; Andrejak, C.; Brochot, E.; Deschasse, G.; Dupont, H.; Goeb, V.; Jaureguy, M.; Lion, S.; et al. Characteristics and outcomes of COVID-19 in hospitalized patients with and without diabetes. Diabetes/Metab. Res. Rev. 2020, 37, e3388. [Google Scholar] [CrossRef]
  21. Holman, N.; Knighton, P.; Kar, P.; O’Keefe, J.; Curley, M.; Weaver, A.; Barron, E.; Bakhai, C.; Khunti, K.; Wareham, N.J.; et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: A population-based cohort study. Lancet Diabetes Endocrinol. 2020, 8, 823–833. [Google Scholar] [CrossRef]
  22. Cariou, B.; Pichelin, M.; Goronflot, T.; Gonfroy, C.; Marre, M.; Raffaitin-Cardin, C.; Thivolet, C.; Wargny, M.; Hadjadj, S.; Gourdy, P. Phenotypic characteristics and prognosis of newly diagnosed diabetes in hospitalized patients with COVID-19: Results from the CORONADO study. Diabetes Res. Clin. Pract. 2021, 175, 108695. [Google Scholar] [CrossRef] [PubMed]
  23. McGurnaghan, S.J.; Weir, A.; Bishop, J.; Kennedy, S.; Blackbourn, L.A.K.; McAllister, D.A.; Hutchinson, S.; Caparrotta, T.M.; Mellor, J.; Jeyam, A.; et al. Risks of and risk factors for COVID-19 disease in people with diabetes: A cohort study of the total population of Scotland. Lancet Diabetes Endocrinol. 2020, 9, 82–93. [Google Scholar] [CrossRef]
  24. Knapp, S. Diabetes and infection: Is there a link?—A mini-Review. Gerontology 2012, 59, 99–104. [Google Scholar] [CrossRef] [PubMed]
  25. Lim, S.; Bae, J.H.; Kwon, H.-S.; Nauck, M.A. COVID-19 and diabetes mellitus: From pathophysiology to clinical management. Nat. Rev. Endocrinol. 2020, 17, 11–30. [Google Scholar] [CrossRef]
  26. Roberts, J.; Pritchard, A.L.; Treweeke, A.T.; Rossi, A.G.; Brace, N.; Cahill, P.; MacRury, S.M.; Wei, J.; Megson, I.L. Why Is COVID-19 More Severe in Patients With Diabetes? The role of angiotensin-converting enzyme 2, endothelial dysfunction and the immunoinflammatory system. Front. Cardiovasc. Med. 2021, 7, 629933. [Google Scholar] [CrossRef]
  27. Bornstein, S.R.; Rubino, F.; Khunti, K.; Mingrone, G.; Hopkins, D.; Birkenfeld, A.L.; Boehm, B.; Amiel, S.; Holt, R.I.; Skyler, J.S.; et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020, 8, 546–550. [Google Scholar] [CrossRef]
  28. Sardu, C.; D’Onofrio, N.; Balestrieri, M.L.; Barbieri, M.; Rizzo, M.R.; Messina, V.; Maggi, P.; Coppola, N.; Paolisso, G.; Marfella, R. Hyperglycaemia on admission to hospital and COVID-19. Diabetologia 2020, 63, 2486–2487. [Google Scholar] [CrossRef]
  29. Alves, C.; Casqueiro, J.; Casqueiro, J. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J. Endocrinol. Metab. 2012, 16, S27–S36. [Google Scholar] [CrossRef]
  30. Cummings, M.J.; Baldwin, M.R.; Abrams, D.; Jacobson, S.D.; Meyer, B.J.; Balough, E.M.; Aaron, J.G.; Claassen, J.; Rabbani, L.E.; Hastie, J.; et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: A prospective cohort study. Lancet 2020, 395, 1763–1770. [Google Scholar] [CrossRef]
  31. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020, 395, 1054–1062. [Google Scholar] [CrossRef]
  32. Wu, C.; Chen, X.; Cai, Y.; Xia, J.; Zhou, X.; Xu, S.; Huang, H.; Zhang, L.; Zhou, X.; Du, C.; et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 2020, 180, 934–943. [Google Scholar] [CrossRef] [PubMed]
  33. Wang, S.; Ma, P.; Zhang, S.; Song, S.; Wang, Z.; Ma, Y.; Xu, J.; Wu, F.; Duan, L.; Yin, Z.; et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: A multi-centre retrospective study. Diabetologia 2020, 63, 2102–2111. [Google Scholar] [CrossRef] [PubMed]
  34. Ikonomidis, I.; Pavlidis, G.; Lambadiari, V.; Kousathana, F.; Varoudi, M.; Spanoudi, F.; Maratou, E.; Parissis, J.; Triantafyllidi, H.; Dimitriadis, G.; et al. Early detection of left ventricular dysfunction in first-degree relatives of diabetic patients by myocardial deformation imaging: The role of endothelial glycocalyx damage. Int. J. Cardiol. 2017, 233, 105–112. [Google Scholar] [CrossRef] [PubMed]
  35. Lambadiari, V.; Pavlidis, G.; Kousathana, F.; Maratou, E.; Georgiou, D.; Andreadou, I.; Kountouri, A.; Varoudi, M.; Balampanis, K.; Parissis, J.; et al. Effects of different antidiabetic medications on endothelial glycocalyx, myocardial function, and vascular function in type 2 diabetic patients: One year follow–up study. J. Clin. Med. 2019, 8, 983. [Google Scholar] [CrossRef]
  36. Zeng, Z.; Yu, H.; Chen, H.; Qi, W.; Chen, L.; Chen, G.; Yan, W.; Chen, T.; Ning, Q.; Han, M.; et al. Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan, China. Crit. Care 2020, 24, 1–12. [Google Scholar] [CrossRef] [PubMed]
  37. Chen, G.; Wu, D.; Guo, W.; Cao, Y.; Huang, D.; Wang, H.; Wang, T.; Zhang, X.; Chen, H.; Yu, H.; et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Investig. 2020, 130, 2620–2629. [Google Scholar] [CrossRef]
  38. Kim, N.-Y.; Ha, E.; Moon, J.S.; Lee, Y.-H.; Choi, E.Y. Acute hyperglycemic crises with coronavirus disease-19: Case reports. Diabetes Metab. J. 2020, 44, 349–353. [Google Scholar] [CrossRef]
  39. Zhu, L.; She, Z.-G.; Cheng, X.; Qin, J.-J.; Zhang, X.-J.; Cai, J.; Lei, F.; Wang, H.; Xie, J.; Wang, W.; et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020, 31, 1068–1077. [Google Scholar] [CrossRef]
  40. Rubino, F.; Amiel, S.A.; Zimmet, P.; Alberti, G.; Bornstein, S.; Eckel, R.H.; Mingrone, G.; Boehm, B.; Cooper, M.E.; Chai, Z.; et al. New-onset diabetes in Covid-19. N. Engl. J. Med. 2020, 383, 789–790. [Google Scholar] [CrossRef]
  41. Lambadiari, V.; Mitrakou, A.; Kountouri, A.; Thymis, J.; Katogiannis, K.; Korakas, E.; Varlamos, C.; Andreadou, I.; Tsoumani, M.; Triantafyllidi, H.; et al. Association of COVID-19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection. Eur. J. Hear. Fail. 2021, 23, 1916–1926. [Google Scholar] [CrossRef]
  42. Kazakou, P.; Paschou, S.A.; Psaltopoulou, T.; Gavriatopoulou, M.; Korompoki, E.; Stefanaki, K.; Kanouta, F.; Kassi, G.N.; Dimopoulos, M.-A.; Mitrakou, A. Early and late endocrine complications of COVID-19. Endocr. Connect. 2021, 10, R229–R239. [Google Scholar] [CrossRef] [PubMed]
  43. Channappanavar, R.; Perlman, S. Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 2017, 39, 529–539. [Google Scholar] [CrossRef] [PubMed]
  44. Li, M.-Y.; Li, L.; Zhang, Y.; Wang, X.-S. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect. Dis. Poverty 2020, 9, 1–7. [Google Scholar] [CrossRef] [PubMed]
  45. Pal, R.; Banerjee, M. COVID-19 and the endocrine system: Exploring the unexplored. J. Endocrinol. Investig. 2020, 43, 1027–1031. [Google Scholar] [CrossRef] [PubMed]
  46. Korytkowski, M.; Antinori-Lent, K.; Drincic, A.; Hirsch, I.B.; McDonnell, M.E.; Rushakoff, R.; Muniyappa, R. A pragmatic approach to inpatient diabetes management during the COVID-19 pandemic. J. Clin. Endocrinol. Metab. 2020, 105, dgaa342. [Google Scholar] [CrossRef]
  47. Mifsud, S.; Schembri, E.L.; Gruppetta, M. Stress-induced hyperglycaemia. Br. J. Hosp. Med. 2018, 79, 634–639. [Google Scholar] [CrossRef]
  48. Drucker, D.J. Coronavirus infections and type 2 diabetes—Shared pathways with therapeutic implications. Endocr. Rev. 2020, 41, 457–470. [Google Scholar] [CrossRef]
  49. Sathish, T.; Kapoor, N.; Cao, Y.; Tapp, R.J.; Zimmet, P. Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Obes. Metab. 2020, 23, 870–874. [Google Scholar] [CrossRef]
  50. Joshi, S.C.; Pozzilli, P. COVID-19 induced diabetes: A novel presentation. Diabetes Res. Clin. Pract. 2022, 191, 110034. [Google Scholar] [CrossRef]
  51. Apicella, M.; Campopiano, M.C.; Mantuano, M.; Mazoni, L.; Coppelli, A.; Del Prato, S. COVID-19 in people with diabetes: Understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020, 8, 782–792. [Google Scholar] [CrossRef]
  52. Rey-Reñones, C.; Baena-Díez, J.M.; Aguilar-Palacio, I.; Miquel, C.; Grau, M. Type 2 diabetes mellitus and cancer: Epidemiology, physiopathology and prevention. Biomedicines 2021, 9, 1429. [Google Scholar] [CrossRef] [PubMed]
  53. Crouse, A.B.; Grimes, T.; Li, P.; Might, M.; Ovalle, F.; Shalev, A. Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes. Front. Endocrinol. 2021, 11, 600439. [Google Scholar] [CrossRef] [PubMed]
  54. Kan, C.; Zhang, Y.; Han, F.; Xu, Q.; Ye, T.; Hou, N.; Sun, X. Mortality risk of antidiabetic agents for type 2 diabetes with COVID-19: A systematic review and meta-analysis. Front. Endocrinol. 2021, 12, 708494. [Google Scholar] [CrossRef] [PubMed]
  55. Takayama, K.; Obata, Y.; Maruo, Y.; Yamaguchi, H.; Kosugi, M.; Irie, Y.; Hazama, Y.; Yasuda, T. Metformin-associated lactic acidosis with hypoglycemia during the COVID-19 pandemic. Intern. Med. 2022, 61, 2333–2337. [Google Scholar] [CrossRef]
  56. Sardu, C.; D’Onofrio, N.; Balestrieri, M.L.; Barbieri, M.; Rizzo, M.R.; Messina, V.; Maggi, P.; Coppola, N.; Paolisso, G.; Marfella, R. Outcomes in patients with hyperglycemia affected by COVID-19: Can we do more on glycemic control? Diabetes Care 2020, 43, 1408–1415. [Google Scholar] [CrossRef]
  57. Galindo, R.J.; Aleppo, G.; Klonoff, D.C.; Spanakis, E.K.; Agarwal, S.; Vellanki, P.; Olson, D.E.; Umpierrez, G.E.; Davis, G.M.; Pasquel, F.J. Implementation of continuous glucose monitoring in the hospital: Emergent considerations for remote glucose monitoring during the COVID-19 pandemic. J. Diabetes Sci. Technol. 2020, 14, 822–832. [Google Scholar] [CrossRef]
  58. Davis, G.M.; Faulds, E.; Walker, T.; Vigliotti, D.; Rabinovich, M.; Hester, J.; Peng, L.; McLean, B.; Hannon, P.; Poindexter, N.; et al. Remote continuous glucose monitoring with a computerized insulin infusion protocol for critically ill patients in a COVID-19 medical ICU: Proof of concept. Diabetes Care 2021, 44, 1055–1058. [Google Scholar] [CrossRef]
  59. Yu, B.; Li, C.; Sun, Y.; Wang, D.W. Insulin treatment is associated with increased mortality in patients with COVID-19 and type 2 diabetes. Cell Metab. 2020, 33, 65–77. [Google Scholar] [CrossRef]
  60. Chen, Y.; Yang, D.; Cheng, B.; Chen, J.; Peng, A.; Yang, C.; Liu, C.; Xiong, M.; Deng, A.; Zhang, Y.; et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care 2020, 43, 1399–1407. [Google Scholar] [CrossRef]
  61. Hahn, K.; Ejaz, A.A.; Kanbay, M.; Lanaspa, M.A.; Johnson, R.J. Acute kidney injury from SGLT2 inhibitors: Potential mechanisms. Nat. Rev. Nephrol. 2016, 12, 711–712. [Google Scholar] [CrossRef]
  62. Nguyen, N.N.; Ho, D.S.; Nguyen, H.S.; Ho, D.K.N.; Li, H.-Y.; Lin, C.-Y.; Chiu, H.-Y.; Chen, Y.-C. Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis. Metabolism 2022, 131, 155196. [Google Scholar] [CrossRef]
  63. Kosiborod, M.N.; Esterline, R.; Furtado, R.H.M.; Oscarsson, J.; Gasparyan, S.B.; Koch, G.G.; Martinez, F.; Mukhtar, O.; Verma, S.; Chopra, V.; et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021, 9, 586–594. [Google Scholar] [CrossRef]
  64. Lv, W.; Wang, X.; Xu, Q.; Lu, W. Mechanisms and characteristics of sulfonylureas and glinides. Curr. Top. Med. Chem. 2020, 20, 37–56. [Google Scholar] [CrossRef] [PubMed]
  65. Yki-Järvinen, H. Thiazolidinediones. N. Engl. J. Med. 2004, 351, 1106–1118. [Google Scholar] [CrossRef] [PubMed]
  66. Mulvihill, E.E. Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism. Peptides 2018, 100, 158–164. [Google Scholar] [CrossRef]
  67. Patoulias, D.; Doumas, M. Dipeptidyl peptidase-4 inhibitors and COVID-19-related deaths among patients with type 2 diabetes mellitus: A meta-analysis of observational studies. Endocrinol. Metab. 2021, 36, 904–908. [Google Scholar] [CrossRef]
  68. Yang, Y.; Cai, Z.; Zhang, J. DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: A meta-analysis. PLoS ONE 2021, 16, e0251916. [Google Scholar] [CrossRef]
  69. Iacobellis, G. COVID-19 and diabetes: Can DPP4 inhibition play a role? Diabetes Res. Clin. Pract. 2020, 162, 108125. [Google Scholar] [CrossRef]
  70. Campbell, J.E.; Drucker, D.J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013, 17, 819–837. [Google Scholar] [CrossRef]
  71. Chen, Y.; Lv, X.; Lin, S.; Arshad, M.; Dai, M. The association between antidiabetic agents and clinical outcomes of COVID-19 patients with diabetes: A bayesian network meta-analysis. Front. Endocrinol. 2022, 13, 895458. [Google Scholar] [CrossRef]
  72. Hulst, A.H.; Plummer, M.P.; Hollmann, M.W.; DeVries, J.H.; Preckel, B.; Deane, A.M.; Hermanides, J. Systematic review of incretin therapy during peri-operative and intensive care. Crit. Care 2018, 22, 299. [Google Scholar] [CrossRef] [PubMed]
  73. Lim, S.; Lee, G.Y.; Park, H.S.; Lee, D.-H.; Jung, O.T.; Min, K.K.; Kim, Y.-B.; Jun, H.-S.; Chul, J.H.; Park, K.S. Attenuation of carotid neointimal formation after direct delivery of a recombinant adenovirus expressing glucagon-like peptide-1 in diabetic rats. Cardiovasc. Res. 2016, 113, 183–194. [Google Scholar] [CrossRef] [PubMed]
  74. Lim, S.; Oh, T.J.; Dawson, J.; Sattar, N. Diabetes drugs and stroke risk: Intensive versus conventional glucose-lowering strategies, and implications of recent cardiovascular outcome trials. Diabetes Obes. Metab. 2019, 22, 6–15. [Google Scholar] [CrossRef] [PubMed]
Biomedicines 10 02089 g001 550
Figure 1. Estimated number of adults with diabetes (20–79 years) in the top 10 countries worldwide in (A) 2019, (B) 2030 and (C) 2045. Data for this figure is obtained from Mathers et al. [2].
Figure 1. Estimated number of adults with diabetes (20–79 years) in the top 10 countries worldwide in (A) 2019, (B) 2030 and (C) 2045. Data for this figure is obtained from Mathers et al. [2].
Biomedicines 10 02089 g001
Biomedicines 10 02089 g002 550
Figure 2. Possible mechanisms behind adverse clinical outcomes of COVID-19 in people with type 2 diabetes mellitus. Adapted from Lim et al. [25].
Figure 2. Possible mechanisms behind adverse clinical outcomes of COVID-19 in people with type 2 diabetes mellitus. Adapted from Lim et al. [25].
Biomedicines 10 02089 g002
Biomedicines 10 02089 g003 550
Figure 3. Potential pathogenic mechanisms of SARS-CoV-2 infection underlying metabolic deregulation and homeostasis alteration. Adapted from Apicella et al. [51].
Figure 3. Potential pathogenic mechanisms of SARS-CoV-2 infection underlying metabolic deregulation and homeostasis alteration. Adapted from Apicella et al. [51].
Biomedicines 10 02089 g003
Table
Table 1. COVID-19 Death in T2DM: Summary of the main results.
Table 1. COVID-19 Death in T2DM: Summary of the main results.
CountrynMortality (%)COVID-19 Death in T2DM
No T2DMT2DMHR (95% CI)
Al-Salameh [20]France43321.517.40.77 (0.44–1.32)
Barron [13]UK61,414,4700.030.262.03 (1.97–2.09)
Bode [14]USA11226.228.8--
De Almeida-Pititto [11]Meta-analysis4,30512.429.92.50 (1.74–3.59)
Diedisheim [15]France631422261.81 (1.14–2.87)
Espiritu [16]Philippines10,88112.926.41.46 (1.28–1.68)
Kim [17]USA10,861----1.20 (1.08–1.32)
Lazarus [12]Meta-analysis14,502----1.81 (1.41–2.33)
Williamson [18]UK17,278,3920.060.261.95 (1.83–2.08)
Wu [19]China44,6722.37.3--
CI, confidence interval. HR, Hazard Ratio. T2DM, type 2 diabetes mellitus.
Table
Table 2. Beneficial and adverse effects and clinical recommendations of antidiabetic treatment for COVID-19.
Table 2. Beneficial and adverse effects and clinical recommendations of antidiabetic treatment for COVID-19.
Anti-Diabetic
Treatment		Beneficial EffectAdverse EffectRecommendations
MetforminAnti-inflammatory effect
Reduction insulin resistance
Inhibition virus entry		Lactic acidosis (kidney damage)Avoid in dehydrated patients
InsulinContinuous glycemic control First treatment
SGLT2 inhibitorsAnti-inflammatory effects Avoid in severely affected patients with COVID-19 and at risk of dehydration
SulfonylureasAnti-inflammatory effectsRisk of hypoglycemiaAvoid in severe COVID-19 disease and combination with chloroquine or hydroxychloroquine treatments
ThiazolidinedionesInsulin resistance improvement
Anti-inflammatory and anti-atherosclerotic effects
and effects		Weight gain and swelling
Heart failure		Not recommended in patients with COVID-19
DPP4 inhibitorsAnti-inflammatory and antifibrotic effects Mild and severe cases of COVID-19
GLP-1 receptor
agonists		Anti-inflammatory effect
Reduction cardiac events
Control glucose homeostasis		Gastrointestinal side effectsControl of blood glucose levels in ICU hospitalized patients
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Rey-Reñones, C.; Martinez-Torres, S.; Martín-Luján, F.M.; Pericas, C.; Redondo, A.; Vilaplana-Carnerero, C.; Dominguez, A.; Grau, M. Type 2 Diabetes Mellitus and COVID-19: A Narrative Review. Biomedicines 2022, 10, 2089. https://doi.org/10.3390/biomedicines10092089

AMA Style

Rey-Reñones C, Martinez-Torres S, Martín-Luján FM, Pericas C, Redondo A, Vilaplana-Carnerero C, Dominguez A, Grau M. Type 2 Diabetes Mellitus and COVID-19: A Narrative Review. Biomedicines. 2022; 10(9):2089. https://doi.org/10.3390/biomedicines10092089

Chicago/Turabian Style

Rey-Reñones, Cristina, Sara Martinez-Torres, Francisco M. Martín-Luján, Carles Pericas, Ana Redondo, Carles Vilaplana-Carnerero, Angela Dominguez, and María Grau. 2022. "Type 2 Diabetes Mellitus and COVID-19: A Narrative Review" Biomedicines 10, no. 9: 2089. https://doi.org/10.3390/biomedicines10092089

APA Style

Rey-Reñones, C., Martinez-Torres, S., Martín-Luján, F. M., Pericas, C., Redondo, A., Vilaplana-Carnerero, C., Dominguez, A., & Grau, M. (2022). Type 2 Diabetes Mellitus and COVID-19: A Narrative Review. Biomedicines, 10(9), 2089. https://doi.org/10.3390/biomedicines10092089

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop